Trials / Recruiting
RecruitingNCT06600022
Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours.
A Phase I/II, Open-label, Multicentre, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics and Anti-tumor Activity of SCTB41 in Patients with Advanced Malignant Solid Tumours
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 441 (estimated)
- Sponsor
- Sinocelltech Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to explore the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB41 as a monotherapy in adult patients with advanced malignant solid tumours. This study is an open label, multicentre, dose-escalation and dose-expansion Phase I/II clinical trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SCTB41 | SCTB41 of different doses,IV,every 3 weeks |
Timeline
- Start date
- 2024-10-10
- Primary completion
- 2027-04-30
- Completion
- 2028-04-30
- First posted
- 2024-09-19
- Last updated
- 2025-01-16
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06600022. Inclusion in this directory is not an endorsement.